ClinicalTrials.gg

Program

ALN-CIDEB

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Liver Diseases, Alcoholic · Obesity, led by Regeneron Pharmaceuticals.

Furthest: phase 3, since Sep 28, 20264 company-led studies, 4 open or runningNext primary completion: Aug 17, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals44 open or runningphase 3since Sep 28, 2026Feb 14, 2025Aug 17, 2027phase 2 · NCT06836609

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 14, 2025First study: phase 2 study in ObesityFirst studyNCT06836609 · 118 enrolled · United States, United Kingdom
  2. Jun 1, 2026Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT07631637 · 360 planned · United States, Puerto Rico, United Kingdom
  3. Sep 28, 2026Phase 3 study in Non-alcoholic Fatty Liver DiseasePhase 3 reachedNCT07854782 · 1,500 planned · United States
  4. Nov 5, 2026Phase 2 study in Liver Diseases, AlcoholicNCT07933328 · 120 planned

Ahead

  1. Aug 17, 2027Primary completion: phase 2 study in ObesityNCT06836609
  2. Jan 29, 2029Primary completion: phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT07631637
  3. Mar 3, 2029Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT07854782
  4. May 7, 2029Primary completion: phase 2 study in Liver Diseases, AlcoholicNCT07933328

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07933328Liver Diseases, Alcoholic2Not yet recruitingMay 7, 2029120
NCT07854782Non-alcoholic Fatty Liver Disease · United States3RecruitingMar 3, 20291,500
NCT07631637Non-alcoholic Fatty Liver Disease · United States, Puerto Rico, United Kingdom2RecruitingJan 29, 2029360
NCT06836609Obesity · United States, United Kingdom2Active, not recruitingAug 17, 2027118

How it is read

Names in the registry

  • “ALN-CIDEB”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.